| 000 | 00931 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250518084004.0 | ||
| 264 | 0 | _c20200213 | |
| 008 | 202002s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(19)33154-X _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHapgood, Janet P | |
| 245 | 0 | 0 |
_aECHO: context and limitations. _h[electronic resource] |
| 260 |
_bLancet (London, England) _c02 2020 |
||
| 300 |
_ae22 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aContraception |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHIV Infections |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aIntrauterine Devices, Copper |
| 650 | 0 | 4 | _aLevonorgestrel |
| 650 | 0 | 4 | _aMedroxyprogesterone Acetate |
| 773 | 0 |
_tLancet (London, England) _gvol. 395 _gno. 10222 _gp. e22 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(19)33154-X _zAvailable from publisher's website |
| 999 |
_c30612434 _d30612434 |
||